NCT01135771已完成1 期
Performance Study Using the OptiScanner on Healthy Diabetics
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 60
- 试验地点
- 2
- 主要终点
- demonstrate the accuracy of the OptiScanner in measuring blood glucose levels in otherwise healthy diabetic subjects when compared to blood glucose levels simultaneously measured on the YSI
研究概览
简要总结
This study is designed to demonstrate the accuracy of the OptiScanner glucose measurement. The accuracy of the test device will be determined using plasma samples collected directly from Type 1 and Type 2 Diabetics using the OptiScanner. Blood samples will simultaneously be collected and measured on YSI 2300 STAT PLUS (YSI) made by YSI Incorporated. These results will be compared to the OptiScanner's glucose measurement.
研究设计
- 研究类型
- Interventional
- 主要目的
- Diagnostic
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Have signed an Informed Consent Form for this study approved by the Institutional Review Board (IRB)
- •Have a documented onset of diabetes ³ 1 year prior to this study
- •Have Type 1 or Type 2 diabetes according to the American Diabetes Association diagnostic criteria
- •Be currently treated with insulin (all regimens) for ³ 1 year and able (as judged by Investigator) and willing to undergo a hypoglycemic challenge and a hyperglycemic challenge; oral diabetes medication in combination with insulin is allowed
- •Be at least 18 but no more than 65 years of age
- •Be willing and able to comply with the requirements of the protocol
- •Be willing to refrain from participating in any other investigational study while enrolled in this study
- •For Female Subjects: Be post-menopausal, sterilized or not of child-bearing potential, or have a negative pregnancy test and have no intention of becoming pregnant between Visit 1 and Visit 2, and be using contraceptive devices or drugs (risk of pregnancy must be lower than 1%).
排除标准
- •Recurrent major hypoglycemia (as judged by the Investigator) or hypoglycemia requiring hospitalization within the last 12 months
- •Have a history of hypoglycemic seizure within the last year
- •Impaired hepatic function measured as AST/ALT ³ two and a half times the upper reference limit or total bilirubin two and a half times the upper reference limit based on analysis from the local laboratory, or at the Investigator's discretion
- •Impaired renal function measured as creatinine ³ 1.5 (females) mg/dL, ³ 1.7 (males) mg/dL based on analysis from the local laboratory, or at the Investigator's discretion
- •Haematocrit or electrolytes (sodium, potassium) outside of normal limits based on analysis from the local laboratory, or at the investigator's discretion.
- •Have Uric Acid > 10 mg/dL based on analysis from the local laboratory
- •HIV positive, or Hepatitis B or C positive (blood test required). A viral load test will be done at the local laboratory for subjects with a positive Hepatitis result.
- •New York Heart Association (NYHA) Class III or IV congestive heart failure
- •Have a history of angina requiring hospitalization or a myocardial infarction within the last 12 months
- •Evidence of intermittent or sustained ventricular or supra-ventricular arrhythmias such as ventricular tachycardia, atrial fibrillation, etc. Holter monitoring may be performed to exclude arrhythmias at the discretion of the investigator.
- •Uncontrolled treated/untreated hypertension (systolic blood pressure ³ 160 mmHg and/or diastolic blood pressure ³ 100 mmHg)
- •Have active diabetic proliferative retinopathy (undergoing treatment)
- •Have active significant recurring skin infections or adhesive allergies, at the Investigator's discretion
- •Have given more than 150 mL of blood within 8 weeks prior to enrollment in this study
- •Currently taking anticoagulants, e.g. Coumadin (warfarin), Marcumar (phenprocoumon). Patients with prolonged activated PTT will not be included in this study.
- •Have received any investigational product or been treated with an invasive device within the past 30 days
- •Mental incapacity, unwillingness or language barrier precluding adequate understanding or co-operation
- •Any chronic illness that, in the judgment of the Investigator, may hinder or confuse compliance with the protocol
- •Any condition (may include clinically significant screening laboratory assessments) which, in the judgement of the Investigator, may increase the risk to the subject or decrease the likelihood of achieving the objectives of the study
- •Pregnancy or breastfeeding
结局指标
主要结局
demonstrate the accuracy of the OptiScanner in measuring blood glucose levels in otherwise healthy diabetic subjects when compared to blood glucose levels simultaneously measured on the YSI
次要结局
- The secondary objective of the study is to demonstrate a blood glucose measurement range of 60 to 500 mg/dL at the hematocrit levels referenced as normal
研究者
研究点 (2)
Loading locations...
相似试验
已完成
不适用
OptiScanner Versus Standard Blood Glucose MonitoringHyperglycemiaNCT01720381OptiScan Biomedical Corporation98
Unknown
不适用
MANAGE Automated Glucose MonitoringICU/CCU Patients Requiring Blood Glucose MonitoringNCT02211300OptiScan Biomedical Corporation230
终止
不适用
Monitoring Glucose Levels in Patients With Myocardial InfarctionAcute Coronary SyndromesHyperglycemiaHypoglycemiaNCT03107806Lars Ryden14
已完成
不适用
A Clinical Study of the C8 MediSensors Optical Glucose Monitor™Diabetes MellitusNCT01726114C8 MediSensors, Inc.86
已完成
不适用
Accuracy of Continuous Glucose Monitoring in Patients With Diabetes. A Prospective Observational StudyDysglycemiaDiabetes MellitusPerioperative ComplicationComplications CirculatoryNCT06297850University Hospital Bispebjerg and Frederiksberg60